Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice implication of its potential use as a therapeutic vaccine

Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice : implication of its potential use as a therapeutic vaccine

Copyright © 2010 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 137(2010), 2 vom: 15. Nov., Seite 190-8
1. Verfasser: Zhou, Cheng (VerfasserIn)
Weitere Verfasser: Peng, Guoping, Jin, Xiaoli, Tang, Jie, Chen, Zhi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2010
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Antibodies Antigens, CD CTLA-4 Antigen Ctla4 protein, mouse DNA, Viral Hepatitis B Surface Antigens Immunoglobulin G Recombinant Fusion Proteins mehr... Vaccines, DNA Interleukin-4 207137-56-2 Interferon-gamma 82115-62-6
Beschreibung
Zusammenfassung:Copyright © 2010 Elsevier Inc. All rights reserved.
Fusion of specific antigens to extracellular domain of cytotoxic-T-lymphocyte-associated antigen 4 (CTLA4) represents a promising approach to increase the immunogenicity of DNA vaccines. We evaluated this interesting approach for its enhancement on HBV-specific immune responses and its antiviral effects in HBV transgenic mice. A fusion plasmid encoding the extracellular domain of CTLA4 linked with HBsAg was constructed. Mice were immunized by this fusion plasmid. Vaccination with the CTLA4-fused DNA not only induced much higher level of anti-HBs antibody, but also increased HBsAg-specific CD8+ response as well as CTL response in BALB/c mice. Furthermore, both Th1 and Th2 responses were augmented. In HBV transgenic mice, the levels of circulating HBsAg and HBV DNA replication were down-regulated by induction of higher anti-HBs antibody and HBsAg-specific CD8+ response after vaccination with the fusion plasmid. Thus, the CTLA4-fused DNA vaccine led to breakdown of immune tolerance to viral infection in HBV transgenic mice, which might be used as a therapeutic vaccine in HBV infection
Beschreibung:Date Completed 17.02.2011
Date Revised 10.12.2019
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2010.07.002